Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma.

Qing YangJiemiao HuZhiliang Jia Qi WangJing WangLong Hoang DaoWendong ZhangSheng ZhangXueqing XiaRichard G Gorlick Shulin Li

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

In summary, attIL12-PBMC therapy is safe and effective against osteosarcoma. Our goal is to move this treatment into a clinical trial. Owing to the convenience of the attIL12-PBMC production process, we believe it will be feasible.

Keyphrases

clinical trial
cancer therapy
randomized controlled trial
open label
phase ii
study protocol
combination therapy
double blind
mesenchymal stem cells